Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine.
AUTOR(ES)
Westrop, G D
RESUMO
The poliovirus type 3 Sabin oral poliovirus vaccine strain P3/Leon/12a1b differs in nucleotide sequence from its neurovirulent progenitor P3/Leon/37 by just 10 point mutations. The contribution of each mutation to the attenuation phenotype of the vaccine strain was determined by the construction of a series of recombinant viruses from infectious cDNA clones. The neurovirulence testing of recombinant viruses indicated that the attenuation phenotype is determined by just two point mutations: a C to U in the noncoding region at position 472 and a C to U at nucleotide 2034 which results in a serine-to-phenylalanine amino acid substitution in the structural protein VP3.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=247831Documentos Relacionados
- Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine.
- Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine.
- Molecular Mechanisms of Attenuation of the Sabin Strain of Poliovirus Type 3
- Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine.
- A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain.
